Source comparison
MOTS-c 50s Age Specific Protocol: Dosing Comparison
Under 40 5–10mg 2–3× weekly 4–6 weeks AMPK activation, acute metabolic shift 2–3 weeks for measurable mitochondrial biogenesis Faster receptor response allows higher acute doses with shorter cycles 40–50 3× weekly 6–8 weeks AMPK activation + mitochondrial dens
This comparison does not assign a generated winner or score.
- Under 40
- 5–10mg
- 2–3× weekly
- 4–6 weeks
- AMPK activation, acute metabolic shift
- 2–3 weeks for measurable mitochondrial biogenesis
- Faster receptor response allows higher acute doses with shorter cycles
- 40–50
- 3× weekly
- 6–8 weeks
- AMPK activation + mitochondrial density support
- 3–4 weeks for measurable mitochondrial biogenesis
- Moderate receptor density requires consistent frequency over intensity
- 50+
- 5mg (conservative start)
- 8–10 weeks
- Mitochondrial biogenesis, cumulative AMPK upregulation
- 4–6 weeks for measurable mitochondrial biogenesis
- Reduced baseline mitochondrial density requires extended cycles and lower starting doses
- 60+
- 5mg
- 10–12 weeks
- Insulin sensitivity restoration, mitochondrial maintenance
- 5–7 weeks for measurable mitochondrial biogenesis
- Prioritise foundational metabolic support (resistance training, protein intake) alongside peptide use
- The primary difference between age brackets isn't the peptide's pharmacology. It's the cellular environment. Younger populations have higher mitochondrial receptor density, faster turnover rates, and more responsive AMPK signaling, which allows shorter cycles at higher doses. The MOTS-c 50s age specific protocol extends cycle duration to allow cumulative mitochondrial adaptation to overcome age-related receptor decline.